<DOC>
	<DOC>NCT00216775</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of low-dose interferon-alfa-2b plus ribavirin compared to the standard-dose of the same combination in patients with chronic hepatitis C.</brief_summary>
	<brief_title>Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Clinical diagnosis of Chronic Hepatitis C. Must be infected with genotype 1b viruses Hemoglobin levels&lt;8.5g/dL, Platelet counts&lt;50,000/mm3, Total polymorphonuclear counts&lt;1000/mm3 Pregnancy, Renal dysfunction,</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>